General
Preferred name
TICLOPIDINE
Synonyms
TICLOPIDINE HYDROCHLORIDE ()
53-32C ()
Ticlodone ()
Ticlopidine HCl ()
Ticlodix ()
PCR 5332 ()
Ticlid ()
Ticlopidine (hydrochloride) ()
Yuclid, Ticlopidinum, Ticlopidina,PCR 5332 ()
NSC-759165 ()
4-C-32 ()
Tiklid ()
Ipaton ()
Ticlopidina ()
Ticlopidin-puren ()
Ticlopidine-d4 (hydrochloride) ()
P&D ID
PD010172
CAS
55142-85-3
53885-35-1
2932627-17-1
Tags
available
prodrug
drug
Approved by
FDA
First approval
1991
Drug indication
internal carotid artery stenosis
Stroke
Drug Status
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Ticlopidine hydrochloride is an adenosine diphosphate (ADP) receptor inhibitor against platelet aggregation with IC50 of ~2 ¦ÌM.;Target: Adenosine diphosphate (ADP);Ticlopidine (trade name Ticlid) is an antiplatelet drug in the thienopyridine family. Ticlopidine hydrochloride inhibits platelet aggregation with IC50 of ~2 ¦ÌM in men. Like clopidogrel, it is an adenosine diphosphate (ADP) receptor inhibitor. It is used in patients in whom aspirin is not tolerated, or in whom dual antiplatelet therapy is desirable. Because it has been reported to increase the risk of thrombotic thrombocytopenic purpura (TTP) and neutropenia, its use has largely been supplanted by the newer drug, clopidogrel, which is felt to have a much lower hematologic risk. Its niche role as an alternative in those patients who do not tolerate Clopidogrel has now been superdeded by Ticagrelor and Prasugrel. The usual dose is 250 mg twice daily by the oral route.;Ticlopidine hydrochloride, when orally administered to rats, results in activation of basal and prostaglandin E1 (PGE1)-stimulated adenylate cylase activity through increase in affinity of the cyclase in platelet membrane to PGE1, although it failed to affect adenosine- or sodium fluoride-stimulated activity of the enzyme.
PRICE 29
INDICATION Used in patients, who have had a stroke or stroke precursors and who cannot take aspirin or aspirin has not worked, to try to prevent another thrombotic stroke.;
TOXICITY Single oral doses of ticlopidine at 1600 mg/kg and 500 mg/kg were lethal to rats and mice, respectively. Symptoms of acute toxicity were GI hemorrhage, convulsions, hypothermia, dyspnea, loss of equilibrium and abnormal gait. The FDA label includes a black-box warning of neutropenia, aplastic anemia, thrombotic thrombocytopenia purpura, and agranulocytosis, so it is necessary to monitor patients' WBC and platelets when they are taking ticlopidine.;
DESCRIPTION Ticlopidine is an antiplatelet drug. This compound is believed to be a prodrug, although the exact form of the active metabolite remains elusive. (GtoPdb)
DESCRIPTION Ticlopidine (PCR 5332), an antithrombotic proagent, acts as an allosteric, noncompetitive inhibitor of CD39 with the IC50 of 81.7 ¦ÌM. Ticlopidine blocks several NTPDase isoenzymes with IC50s of 170 ¦ÌM and 149 ¦ÌM for NTPDase2 and NTPDase3, respectively. Ticlopidine is an inhibitor of CYP2C19 human liver cytochrome. Ticlopidine inhibits CYP2C9 and CYP3A4 with IC50s of 26.0 and 32.3 ¦ÌM, respectively.
PRICE 29
DESCRIPTION Ticlopidine hydrochloride (Ticlodix) is an effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES. (TargetMol Bioactive Compound Library)
DESCRIPTION Ticlopidine is an antiplatelet drug in the thienopyridine family. It is used in the prevention of conditions associated with thrombi, such as stroke and transient ischemic attacks. Ticlopyridine inhibits Cytochrome P450 2B6. (Enamine Bioactive Compounds)
DESCRIPTION Ticlopidine (PCR 5332) is an antiplatelet drug in the thienopyridine family which is an adenosine diphosphate (ADP) receptor inhibitor. (TargetMol Bioactive Compound Library)
Cell lines
1
Organisms
0
Compound Sets
32
AdooQ Bioactive Compound Library
A11690
Cayman Chemical Bioactives
20770
33467
ChEMBL Approved Drugs
CHEMBL1717
CHEMBL833
ChEMBL Drugs
CHEMBL1717
CHEMBL833
Concise Guide to Pharmacology 2019/20
7307
Concise Guide to Pharmacology 2021/22
7307
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB00208
DrugBank Approved Drugs
DB00208
DrugCentral
2657
DrugCentral Approved Drugs
2657
DrugMAP
DMO946V
DrugMAP Approved Drugs
DMO946V
DrugMatrix
Enamine Bioactive Compounds
EBC-06095
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS101656
Guide to Pharmacology
7307
Ki Database
Ticlopidine
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL833
Mcule NIBR MoA Box Subset
MCULE-3971692083
MedChem Express Bioactive Compound Library
HY-B0153A
HY-100386
NCATS Inxight Approved Drugs
OM90ZUW7M1
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
ticlopidine-hydrochloride
ticlopidine
TargetMol Bioactive Compound Library
T0362
T4190
The Spectrum Collection
External IDs
68
Properties
(calculated by RDKit )
Molecular Weight
263.05
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
0
Rotatable Bonds
2
Ring Count
3
Aromatic Ring Count
2
cLogP
3.96
TPSA
3.24
Fraction CSP3
0.29
Chiral centers
0.0
Largest ring
6.0
QED
0.79
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
ADP
P2RY12
Adenosine Receptor
Adenosine Receptor,P450 (e.g. CYP17)
P2 Receptor
Cytochrome P450
Member status
member
MOA
P2Y12 (P2T) Antagonists
purinergic receptor antagonist
Indication
thrombosis, stroke
Disease Area
hematology, neurology/psychiatry
Pathway
GPCR/G protein
Neuroscience
Metabolic Enzyme/Protease
Membrane Transporter/Ion Channel
Therapeutic Class
Fibrinolytic Agents
Source data